top of page

Toutes mes Publications

​

  1. Gal J, Milano G, Brest P et al. VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy-A Message from COMET, a French Unicancer Multicentric Study. Pharmaceuticals (Basel) 2020; 13.

  2. Gal J, Bailleux C, Chardin D et al. Comparison of unsupervised machine-learning methods to identify metabolomic signatures in patients with localized breast cancer. Comput Struct Biotechnol J 2020; 18: 1509-1524.

  3. Gilhodes J, Dalenc F, Gal J et al. Comparison of Variable Selection Methods for Time-to-Event Data in High-Dimensional Settings. Comput Math Methods Med 2020; 2020: 6795392.

  4. Sumodhee S, Pujalte M, Gal J et al. Accelerated partial breast irradiation in the elderly: 8-year oncological outcomes and prognostic factors. Brachytherapy 2020.

  5. Refae S, Gal J, Ebran N et al. Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Invest New Drugs 2020; 38: 160-171.

  6. Refae S, Gal J, Brest P et al. Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics. Sci Rep 2020; 10: 3565.

  7. Milano G, Gal J. Comment on: "Exploring the best treatment options for BRAF-mutant metastatic colon cancer". Br J Cancer 2020; 122: 1724-1725.

  8. Hannoun-Lévi JM, Lam Cham Kee D, Gal J et al. Accelerated partial breast irradiation in the elderly: 5-Year results of the single fraction elderly breast irradiation (SiFEBI) phase I/II trial. Brachytherapy 2020; 19: 90-96.

  9. Elaldi R, Roussel LM, Gal J et al. Correlations between long-term quality of life and patient needs and concerns following head and neck cancer treatment and the impact of psychological distress. A multicentric cross-sectional study. Eur Arch Otorhinolaryngol 2020.

  10. D'Andréa G, Scheller B, Gal J et al. How to select candidates for microvascular head and neck reconstruction in the elderly? Predictive factors of postoperative outcomes. Surg Oncol 2020; 34: 168-173.

  11. Cesaretti M, Gal J, Bouveyron C et al. Accurate assessment of nonalcoholic fatty liver disease lesions in liver allograft biopsies by a smartphone platform: A proof of concept. Microsc Res Tech 2020; 83: 1025-1031.

  12. Bozec A, Majoufre C, De Boutray M et al. Oral and oropharyngeal cancer surgery with free-flap reconstruction in the elderly: Factors associated with long-term quality of life, patient needs and concerns. A GETTEC cross-sectional study. Surg Oncol 2020; 35: 81-88.

  13. Bouhlel L, Doyen J, Chamorey E et al. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bull Cancer 2020; 107: 946-958.

  14. Sumodhee S, Bondiau PY, Poudenx M et al. Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer. BMC Cancer 2019; 19: 305.

  15. Refae S, Gal J, Brest P, Milano G. Germinal immunogenetics as a predictive factor for immunotherapy. Crit Rev Oncol Hematol 2019; 141: 146-152.

  16. Montagne L, Gal J, Chand ME et al. GEC-ESTRO APBI classification as a decision-making tool for the management of 2nd ipsilateral breast tumor event. Breast Cancer Res Treat 2019; 176: 149-157.

  17. Kinj R, Chand ME, Gal J et al. Five-year oncological outcome after a single fraction of accelerated partial breast irradiation in the elderly. Radiat Oncol 2019; 14: 234.

  18. Humbert O, Bourg V, Mondot L et al. <sup>18</sup>F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions. Eur J Nucl Med Mol Imaging 2019; 46: 558-568.

  19. Gérard JP, Barbet N, Gal J et al. Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study. Eur J Cancer 2019; 108: 1-16.

  20. Bozec A, Schultz P, Gal J et al. Evaluation of the information given to patients undergoing total pharyngolaryngectomy and quality of life: a prospective multicentric study. Eur Arch Otorhinolaryngol 2019; 276: 2531-2539.

  21. Bozec A, Schultz P, Gal J et al. Evolution and predictive factors of quality of life in patients undergoing oncologic surgery for head and neck cancer: A prospective multicentric study. Surg Oncol 2019; 28: 236-242.

  22. Bondiau PY, Gal J, Chapellier C et al. Robotic Stereotactic Boost in Early Breast Cancer, a Phase 2 Trial. Int J Radiat Oncol Biol Phys 2019; 103: 374-380.

  23. Tardy MP, Gal J, Chamorey E et al. Quality of Randomized Controlled Trials Reporting in the Treatment of Adult Patients with High-Grade Gliomas. Oncologist 2018; 23: 337-345.

  24. Pescetto B, Gal J, Chamorey E et al. Role of supracricoid partial laryngectomy with cricohyoidoepiglottopexy in glottic carcinoma with anterior commissure involvement. Eur Ann Otorhinolaryngol Head Neck Dis 2018; 135: 249-253.

  25. Milliet F, Gal J, Chamorey E et al. Total pharyngolaryngectomy in the elderly: The impact of age on postoperative complications and oncologic and functional outcomes. Surg Oncol 2018; 27: 767-772.

  26. Kinj R, Chand ME, Gal J et al. Single fraction of accelerated partial breast irradiation in the elderly: early clinical outcome. Radiat Oncol 2018; 13: 174.

  27. Kee DLC, Gal J, Falk AT et al. Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials. Cancer Treat Rev 2018; 70: 265-271.

  28. Hannoun-Lévi JM, Cham Kee DL, Gal J et al. Accelerated partial breast irradiation for suitable elderly women using a single fraction of multicatheter interstitial high-dose-rate brachytherapy: Early results of the Single-Fraction Elderly Breast Irradiation (SiFEBI) Phase I/II trial. Brachytherapy 2018; 17: 407-414.

  29. Gal J, Milano G, Ferrero JM et al. Optimizing drug development in oncology by clinical trial simulation: Why and how? Brief Bioinform 2018; 19: 1203-1217.

  30. Fournier M, Radel R, Bailly L et al. \"As du Coeur\" study: a randomized controlled trial on physical activity maintenance in cardiovascular patients. BMC Cardiovasc Disord 2018; 18: 77.

  31. Doyen J, Poudenx M, Gal J et al. Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial. Radiother Oncol 2018; 127: 239-245.

  32. Bozec A, Demez P, Gal J et al. Long-term quality of life and psycho-social outcomes after oropharyngeal cancer surgery and radial forearm free-flap reconstruction: A GETTEC prospective multicentric study. Surg Oncol 2018; 27: 23-30.

  33. Bailly L, Mossé P, Diagana S et al. \"As du Coeur\" study: a randomized controlled trial on quality of life impact and cost effectiveness of a physical activity program in patients with cardiovascular disease. BMC Cardiovasc Disord 2018; 18: 225.

  34. Zangari J, Ilie M, Rouaud F et al. Rapid decay of engulfed extracellular miRNA by XRN1 exonuclease promotes transient epithelial-mesenchymal transition. Nucleic Acids Res 2017; 45: 4131-4141.

  35. Saâda-Bouzid E, Defaucheux C, Karabajakian A et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017; 28: 1605-1611.

  36. Marcy PY, Schiappa R, Ferrero JM et al. Patient satisfaction and acceptance of their totally implanted central venous catheter: a French prospective multicenter study. J Vasc Access 2017; 18: 390-395.

  37. Frin AC, Evesque L, Gal J et al. Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients. Eur J Cancer 2017; 72: 124-136.

  38. Dufies M, Giuliano S, Viotti J et al. CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas. Br J Cancer 2017; 117: 947-953.

  39. Dassonville O, Bozec A, Château Y et al. Multicenter prospective micro-costing study evaluating mandibular free-flap reconstruction. Eur Arch Otorhinolaryngol 2017; 274: 1103-1111.

  40. Reure J, Follana P, Gal J et al. Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX. Oncology 2016; 90: 261-266.

  41. Fournier M, Radel R, Tifratene K et al. Protocol of the \"As du Coeur\" study: a randomized controlled trial on physical activity maintenance in cardiovascular patients. BMC Cardiovasc Disord 2016; 16: 160.

  42. Dugué AE, Pulido M, Chabaud S et al. How to Deal with Interval-Censored Data Practically while Assessing the Progression-Free Survival: A Step-by-Step Guide Using SAS and R Software. Clin Cancer Res 2016; 22: 5629-5635.

  43. Bozec A, Schultz P, Gal J et al. Evaluation of the information given to patients undergoing head and neck cancer surgery using the EORTC QLQ-INFO25 questionnaire: A prospective multicentric study. Eur J Cancer 2016; 67: 73-82.

  44. Barriere J, Mari V, Cherikh F et al. [Adaptation and validation of a brief screening questionnaire of depressive disorders in patients with cancer: Q2i study]. Bull Cancer 2016; 103: 138-147.

  45. Saâda-Bouzid E, Burel-Vandenbos F, Ranchère-Vince D et al. Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. Mod Pathol 2015; 28: 1404-1414.

  46. Moureau-Zabotto L, Gal J, Resbeut M et al. [Management and clinical outcome in patients over 80 years with rectal cancer treated between 2006 and 2008 in Southern France (PACA region)]. Cancer Radiother 2015; 19: 725-732.

  47. Gerard JP, Frin AC, Doyen J et al. Organ preservation in rectal adenocarcinoma (T1) T2-T3 Nx M0. Historical overview of the Lyon Sud - nice experience using contact x-ray brachytherapy and external beam radiotherapy for 120 patients. Acta Oncol 2015; 54: 545-551.

  48. Ezzalfani M, Dugué A, Mollevi C et al. [The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]. Bull Cancer 2015; 102: 73-82.

  49. Brucker-Davis F, Ganier-Chauliac F, Gal J et al. Neurotoxicant exposure during pregnancy is a confounder for assessment of iodine supplementation on neurodevelopment outcome. Neurotoxicol Teratol 2015; 51: 45-51.

  50. Rouscoff Y, Falk AT, Durand M et al. High-dose rate brachytherapy in localized penile cancer: short-term clinical outcome analysis. Radiat Oncol 2014; 9: 142.

  51. Lee JW, Chevallier D, Gal J et al. [Salvage HIFU after radiotherapy and salvage radiotherapy after HIFU in locally recurrent prostate cancer: Retrospective analysis of morbidity]. Prog Urol 2014; 24: 1076-1085.

  52. Genebes C, Chand ME, Gal J et al. Accelerated partial breast irradiation in the elderly: 5-year results of high-dose rate multi-catheter brachytherapy. Radiat Oncol 2014; 9: 115.

  53. Doyen J, Trastour C, Ettore F et al. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem Biophys Res Commun 2014; 451: 54-61.

  54. Bonnetain F, Bonsing B, Conroy T et al. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). Eur J Cancer 2014; 50: 2983-2993.

  55. Benhaïm C, Chand M, Gal J et al. [Prostate cancer boost using high-dose-rate brachytherapy: impact of the learning curve on the dosimetry]. Cancer Radiother 2014; 18: 659-665.

  56. Vandenbos F, Gal J, Radicchi B. [Vaccination coverage against influenza and pneumococcus for patients admitted to a pulmonary care service]. Rev Mal Respir 2013; 30: 746-751.

  57. Moureau-Zabotto L, Resbeut M, Gal J et al. Management and clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2006 and 2008. J Surg Oncol 2013; 108: 450-456.

  58. Hijazi H, Chevallier D, Gal J et al. Prostate cancer boost using high-dose-rate brachytherapy: early toxicity analysis of 3 different fractionation schemes. J Contemp Brachytherapy 2013; 5: 203-209.

  59. Hiéronimus S, Ferrari P, Gal J et al. Relative impact of iodine supplementation and maternal smoking on cord blood thyroglobulin in pregnant women with normal thyroid function. Eur Thyroid J 2013; 1: 264-273.

  60. Hannoun-Levi JM, Resch A, Gal J et al. Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiother Oncol 2013; 108: 226-231.

  61. Doyen J, Benezery K, Follana P et al. Predictive factors for early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy. Dis Colon Rectum 2013; 56: 1125-1133.

  62. Brucker-Davis F, Panaïa-Ferrari P, Gal J et al. Iodine Supplementation throughout Pregnancy Does Not Prevent the Drop in FT4 in the Second and Third Trimesters in Women with Normal Initial Thyroid Function. Eur Thyroid J 2013; 2: 187-194.

  63. Lutringer J, Flipo B, Carles M et al. [Functional impairment and its impact on sporting activities after latissimus dorsi flap breast reconstruction]. Ann Chir Plast Esthet 2012; 57: 567-574.

  64. Guerin O, Gal J, Francois E et al. Clinical outcome of rectal cancer in patients ≥ 80&nbsp;years treated in southern France (PACA region) between 2002 and 2005. Strahlenther Onkol 2012; 188: 383-387.

  65. Gerard JP, Rostom Y, Gal J et al. Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: lessons from a systematic review of recent randomized trials. Crit Rev Oncol Hematol 2012; 81: 21-28.

  66. Gérard JP, Baulieux J, Doyen J et al. Towards a \"Lyon molecular signature\" to individualize the treatment of rectal cancer. Prognostic analysis of a prospective cohort of 94 rectal cancers T1-2-3 Nx MO to be the basis of a molecular signature. Cancer Radiother 2012; 16: 688-696.

  67. Filleron T, Gal J, Kramar A. Designing group sequential randomized clinical trials with time to event end points using a R function. Comput Methods Programs Biomed 2012; 108: 113-128.

  68. Fénichel P, Déchaux H, Harthe C et al. Unconjugated bisphenol A cord blood levels in boys with descended or undescended testes. Hum Reprod 2012; 27: 983-990.

  69. Brucker-Davis F, Ferrari P, Gal J et al. Iodine status has no impact on thyroid function in early healthy pregnancy. J Thyroid Res 2012; 2012: 168764.

  70. Vandenbos F, Gal J, Dandine M et al. [Assessing the wearing of jewellery by French healthcare professionals]. Med Mal Infect 2011; 41: 192-196.

  71. Brucker-Davis F, Ferrari P, Boda-Buccino M et al. Cord blood thyroid tests in boys born with and without cryptorchidism: correlations with birth parameters and in utero xenobiotics exposure. Thyroid 2011; 21: 1133-1141.

  72. Courdi A, Doyen J, Gal J, Chamorey E. Local recurrence after breast cancer affects specific survival differently according to patient age. Oncology 2010; 79: 349-354.

  73. Brucker-Davis F, Wagner-Mahler K, Bornebusch L et al. Exposure to selected endocrine disruptors and neonatal outcome of 86 healthy boys from Nice area (France). Chemosphere 2010; 81: 169-176.

  74. Liste chronologique des communications orales

Communications orales​

Liste des communications orales

Communications Orales

  1. Guyomard M, Ouizeman D, Schiappa R, Gilet C, Gal J, Chamorey E, Patouraux S, Piche T, Tran A, Gual P, Iannelli A, Fillatre L, Anty R. Diagnostic non invasif de la NASH fibrosante à l’aide de l’intelligence artificielle, 87ème Journées de l’AFEF, Paris, France

  2. Gal J, Bailleux C, Chardin D, Pourcher T, Schiappa R, Gilhodes J, Humbert O et Chamorey E. Comparaison de différentes méthodes d’apprentissage non-supervisé dans le cas de données de grandes dimensions. Application dans le cancer du sein. EPICLIN 12 / 25èmes Journées des Statisticiens des CLCC, Mai 2019, Toulouse, France.

  3. Gal J, Milano G, Bailleux C, Ettaiche M, Paquet A, Gougis P, Borchiellini D, Ferrero JM et Chamorey E. Optimisation du processus de développement d’un nouveau médicament par modélisation et simulation: état des lieux et enjeux. EPICLIN 10 / 23èmes Journées des Statisticiens des CLCC, Mai 2017, Strasbourg, France.

  4. Hannoun-Levi JM, Gal J, Van Limbergen E, Chand ME, Schiappa R, Smanyko V, Kauer-Domer D, Pasquier D, Lemanski C, Racadot S, Houvenaeghel G, Guix B, Belliere-Calandry A, Loessl K, Polat B, Gutierrez C, Galalae R, Polgar C,  Strnad V. Salvage mastectomy versus second conservative treatment for second ipsilateral breast tumour event: A propensity score-matched cohort analysis of the GEC-ESTRO Breast Cancer Working Group database. ASTRO Annual meeting, October 2018,  San Antonio, Etats-Unis.

  5. Dugué A, Gal J, Chabaud S, Boussetta S, Bellera C, Pulido M, Gourgou S, Mollevi C, Filleron T, Ezzalfani M, Le Tourneau C, Le Deley M-C, Schwob D, Paoletti X. Harmonisation des fiches de recueil des toxicités dose-limitante (DLT) dans les essais cliniques de phase I d’oncologie des CLCC/23emes Journées des Statisticiens des CLCC, Mai 2016, Strasbourg, France

  6. Gal J, Bozec A, Poissonnet G, Santini J, Chamorey E, Dassonville O. Etude Prospective Evaluant le Coût de la Reconstruction Mandibulaire par Transplants Osseux Vascularisés Libres (TOVL) et Implants Osteo-Intégrés en Pathologie Tumorale Bucco-Pharyngée/ 20emes Journées des Statisticiens des CLCC, Juin 2013, Marseille, France

  7. Gal J, Kramar A, Chamorey E, Filleron T. Planification d'essais randomisés séquentiels ayant comme critère de jugement un délai de survie à l'aide de la fonction plansurvct.func/ 1eres Rencontres R, Juillet 2012, Bordeaux, France

  8. Gal J, Tuleau C , Ferrero JM, Lovera C, Château Y, Courdi C, Sudaka A, Flippo B, Maestro C, Chamorey E.  Constitution de catégories pronostiques chez les patientes atteintes de cancer du sein après 70 ans : Application de la méthode de segmentation CART/ 18emes Journées des Statisticiens des CLCC, Juin 2011, Lille, France

​

Ouvrages

Ouvrages

  1. Gal J et Gilhodes J. Chapitre : « Analyse statistique des données d’expression de gènes issues de puces à ADN » du livre (réactualisation) Méthodes biostatistiques appliquées à la recherche clinique en cancérologie : John Libbey Eurotext; (1er semestre 2021).

  2. Chamorey E, Gal J, Houede N, Paoletti X. Chapitre: «Planification d'un essai de phase I » du livre Méthodes biostatistiques appliquées à la recherche clinique en cancérologie: John Libbey Eurotext; 2011.

Communications affichées

Communications Affichées

  1. Gal J, Bailleux C, Chardin D, Pourcher T, Jing L, Guigonis JM, Ferrero JM, Schiappa R, Chamorey E and Humbert O. Unsupervised machine learning methods reveal metabolomic based clusters in breast cancer patients. American Association for Cancer Research (AACR), Avril, 2019, Atlanta, Etats-Unis.

  2. Refae S, Gal J, Ebran N, Otto J, Borchiellini D, Peyrade F, Chamorey E, Brest P, Milano G, Saada-bouzid E. germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. American Association for Cancer Research (AACR), Avril, 2019, Atlanta, Etats-Unis.

  3. Refae S, Ebran N, Gal J, Otto J, Giacchero D, Borchiellini D, Peyrade F, Milano G, Saada-bouzid E. Host Immunogenetics and hyperprogressive disease under PD1/PDL-1 Check point inhibitors. American Association for Cancer Research (AACR), Avril, 2018, Chicago, Etats-Unis.

  4. Gal J, Milano G, Viotti J, Schiappa R, Dugué A, Paquet A, Chabaud S, Ferrero JM and Chamorey E. Optimizing drug regimens in oncology by clinical trial simulations: Why and how. American Association for Cancer Research (AACR), April, 2017, Washington, Etats-Unis

  5. Pharmacogenetics revisits bevacizumab in breast cancer patients – An ancillary analysis of the UCBG trial COMET, a French multicentric prospective study from R&D UNICANCER. American Society of Clinical Oncology (ASCO), Juin, 2017, Chicago, Etats-Unis.

  6. Dugué AE, Gal J, Pulido M, Belin L, Chabaud S. Comment analyser les données censurées par intervalle en oncologie/ 22emes Journées des Statisticiens des CLCC, Juin 2015, Montpellier, France

Communications orales invitées, communications didactiques

Communications Orales Invitées

  1. Gal J, Boher JM, Kwiatowski F. Analyses intermédiaires lors d’un essai de phase III/ 5èmes Journées des méthodologistes, GIRCI Sud Méditerranée, Octobre 2015, Marseille, France

bottom of page